Deutsche Bank AG Reduces Stake in Alector, Inc. (NASDAQ:ALEC)

Deutsche Bank AG trimmed its position in shares of Alector, Inc. (NASDAQ:ALEC) by 4.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,106,287 shares of the company’s stock after selling 48,050 shares during the quarter. Deutsche Bank AG owned approximately 1.13% of Alector worth $2,091,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. SG Americas Securities LLC raised its stake in shares of Alector by 27.9% during the 4th quarter. SG Americas Securities LLC now owns 39,334 shares of the company’s stock worth $74,000 after buying an additional 8,581 shares during the last quarter. Apollon Wealth Management LLC purchased a new position in Alector during the 4th quarter valued at about $47,000. Vontobel Holding Ltd. raised its position in Alector by 127.3% during the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $47,000 after acquiring an additional 14,000 shares during the last quarter. Los Angeles Capital Management LLC lifted its holdings in shares of Alector by 61.2% in the fourth quarter. Los Angeles Capital Management LLC now owns 90,736 shares of the company’s stock valued at $171,000 after purchasing an additional 34,450 shares in the last quarter. Finally, Intech Investment Management LLC lifted its holdings in shares of Alector by 83.5% in the fourth quarter. Intech Investment Management LLC now owns 35,382 shares of the company’s stock valued at $67,000 after purchasing an additional 16,096 shares in the last quarter. 85.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ALEC has been the subject of a number of recent research reports. Morgan Stanley reissued an “underweight” rating and set a $1.50 price objective (down from $3.00) on shares of Alector in a research note on Friday, March 7th. HC Wainwright increased their target price on Alector from $7.00 to $10.00 and gave the company a “buy” rating in a report on Friday, May 9th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Alector currently has an average rating of “Hold” and a consensus target price of $4.00.

Alector Price Performance

Shares of NASDAQ ALEC opened at $1.31 on Friday. The company has a 50-day simple moving average of $1.14 and a 200-day simple moving average of $1.89. The company has a market cap of $130.99 million, a PE ratio of -0.77 and a beta of 0.76. Alector, Inc. has a 12 month low of $0.87 and a 12 month high of $6.78.

Alector (NASDAQ:ALEC) last released its earnings results on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.59. The firm had revenue of $54.24 million during the quarter, compared to analysts’ expectations of $20.41 million. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. On average, analysts anticipate that Alector, Inc. will post -1.88 EPS for the current year.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.